Cargando…

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis

Pulmonary drug delivery has long been used for local and systemic administration of different medications used in acute and chronic respiratory diseases. Certain lung diseases, such as cystic fibrosis, rely heavily on chronic treatments, including targeted lung delivery. Pulmonary drug delivery poss...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Xiaoxuan, Li, Danni, Reyes-Ortega, Felisa, Schneider-Futschik, Elena K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223735/ https://www.ncbi.nlm.nih.gov/pubmed/37242730 http://dx.doi.org/10.3390/pharmaceutics15051488

Ejemplares similares

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
por: Li, Danni, et al.
Publicado: (2023)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders
por: Schneider-Futschik, Elena K., et al.
Publicado: (2021)

Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis
por: Harwood, Kiera H., et al.
Publicado: (2021)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
por: Knap, Karolina, et al.
Publicado: (2022)

Ocular development after highly effective modulator treatment early in life
por: Zhu, Yimin, et al.
Publicado: (2023)

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
por: Wilson, Robert, et al.
Publicado: (2013)

Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
por: Chennakesavulu, S., et al.
Publicado: (2018)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Optimizing Spray-Dried Porous Particles for High Dose Delivery with a Portable Dry Powder Inhaler
por: Son, Yoen-Ju, et al.
Publicado: (2021)

Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems
por: Mehta, Piyush
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers
por: Muralidharan, Priya, et al.
Publicado: (2014)

Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
por: Martínez-García, Miguel Ángel, et al.
Publicado: (2020)

Cepharanthine Dry Powder Inhaler for the Treatment of Acute Lung Injury
por: Liang, Di, et al.
Publicado: (2023)

Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler
por: Dolovich, Myrna B., et al.
Publicado: (2019)

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013)

Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery
por: Hassanpour Aghdam, Mehdi, et al.
Publicado: (2016)

Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery
por: Rashid, Md Abdur, et al.
Publicado: (2019)

Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization
por: Rashid, Md Abdur, et al.
Publicado: (2021)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Spray freeze drying of small nucleic acids as inhaled powder for pulmonary delivery
por: Liang, Wanling, et al.
Publicado: (2018)

Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
por: Lu, Peng, et al.
Publicado: (2022)

An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation
por: Marante, Tânia, et al.
Publicado: (2020)

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers
por: Zhang, Tongtong, et al.
Publicado: (2018)

Feedback systems in multi-dose dry powder inhalers
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
por: Lam, John, et al.
Publicado: (2013)

Influence of physical properties of carrier on the performance of dry powder inhalers
por: Peng, Tingting, et al.
Publicado: (2016)

Recent advances in capsule-based dry powder inhaler technology
por: Lavorini, Federico, et al.
Publicado: (2017)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2020)

Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
por: Elson, Elizabeth Claire, et al.
Publicado: (2019)

Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering
por: Mehta, Piyush
Publicado: (2018)

Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development
por: Mohan, Abhinav Ram, et al.
Publicado: (2022)

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome
por: Heirali, Alya A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v0jeocedb6isccqrp4q3pu4s49